BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Diagnóstico y tratamiento de sífilis recomendaciones para los equipos de salud.
Limited research has examined factors associated with psychological distress following natural
disasters among non-Western child populations. Conditions associated with trauma-related symptoms following the 2004 tsunami in a sample of 265 Sri Lankan child survivors (53.6% female, aged 3 to 17) were... examined retrospectively. Multivariate regression analyses identified pre-traumatic conditions (female gender, prior health) and peritraumatic conditions (loss of family, complete property loss) as being associated with increased trauma-related symptoms. Findings can be applied to the identification of children most at risk of developing trauma-related symptoms following a natural disaster from a non-Western population to aid development of culturally-appropriate interventions.
more
This document is an output of a WHO cross-programme initiative aiming to improve the prevention, diagnosis and management of anaemia and thereby accelerate reduction in its prevalence. It comes at an important time, midway through the era of the Sustainable Development Goals, when progress in reduci...ng anaemia has stagnated. This framework is based on the core principles of primary health care: meeting people’s health needs through comprehensive promotive, protective, curative, and rehabilitative care along the life course; systematically addressing the broader determinants of health; and empowering individuals, families, and communities to optimize their health
more
28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.
Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t...reatment of acute and chronic heart failure published in 2016, and summarises what is considered the best current management of patients with the condition. It provides information on the definition, diagnosis and epidemiology of HFrEF in the African context. The best evidence-based treatments for HFrEF are discussed, including established therapies (beta-blockers, ACE-i/ARBs, mineralocorticoid receptor antagonists (MRAs), diuretics) that form the cornerstone of heart failure management as well as therapies that have only recently entered clinical use (angiotensin receptor-neprilysin inhibitor (ARNI), sodium/glucose cotransporter-2 (SGLT2) inhibitors). Guidance is offered in terms of more invasive therapies (revascularisation, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) by implantation of a biventricular pacemaker with (CRT-D) or without (CRT-P) an ICD, left ventricular assist device (LVAD) use and heart transplantation) in order to ensure efficient use of these expensive treatment modalities in a resourcelimited environment. Furthermore, additional therapies (digoxin, hydralazine and nitrates, ivabradine, iron supplementation) are discussed and advice is provided on general preventive strategies (vaccinations). Sections to discuss conditions that are particularly prevalent in sub-Saharan Africa (HIV-associated cardiomyopathy (CMO), peripartum CMO, rheumatic heart disease, atrial fibrillation) have been added to further improve clinical care for these commonly encountered disease processes.
more
The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death... and disability. Atrial fibrillation (AF) is one of these conditions and is an increasing problem due to ageing of the world’s population and an increase in cardiovascular risk factors that predispose to AF. The goal of the AF roadmap was to provide guidance on priority interventions that are feasible in multiple countries, and to identify roadblocks and potential strategies to overcome them.
more
Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ...strongly linked to an increase risk of PAD. Although PAD has been historically underappreciated compared to coronary artery disease and stroke, greater attention on PAD in recent years has led to important new epidemiologic insights in the areas of thrombosis, inflammation, dyslipidemia, and microvascular disease. In addition, the concept of polyvascular disease, or clinically-evident atherosclerosis in multiple arterial beds, is increasingly identified as a particularly malignant cardiovascular disease worthy of special clinical attention and further study. It is noteworthy that PAD may increase the risk of adverse outcomes in similar or even greater magnitude than coronary disease or stroke. In this review, we highlight important new advances in the epidemiology of PAD with a particular focus on polyvascular disease, emerging biomarkers, and differential risk pathways for PAD compared to other atherosclerotic diseases.
more
Version 1.1. The WHO protocol has been adapted to resource-limited settings and builds on existing methodologies from the European Centre for Disease Prevention and Control (ECDC), the Global PPS project from University of Antwerp, the US Centers for Disease Control and Prevention (CDC), and the Med...icines Utilisation Research in Africa (MURIA).
Point Prevalence Surveys collects information on prescribing practices of antibiotics and other information relevant to treatment and management of infectious diseases in hospitalized patients, and complements surveillance of antimicrobial consumption.
more
RÉSUMÉ D’ORIENTATION
L’objectif des présentes orientations est de renforcer la capacité des établissements de santé à protéger et à améliorer la santé des communautés desservies face à un climat instable et changeant ; et de donner aux établissements de santé les moyens d’assur...er leur durabilité environnementale, grâce à une meilleure utilisation des ressources et à une diminution du rejet de déchets dans l’environnement. En étant résilients au changement climatique et écologiquement viables, les établissements de santé peuvent offrir des soins de qualité et des services plus accessibles, et en contribuant à réduire les coûts des établissements, ils garantissent également la prestation de soins plus abordables. Ils représentent par conséquent un élément important de la couverture sanitaire universelle (CSU).
Le présent document a pour objectif de :
guider les professionnels travaillant dans des structures de soins de santé de manière à ce qu’ils comprennent les risques sanitaires supplémentaires liés au changement climatique et qu’ils s’y préparent efficacement ;
renforcer la capacité à exercer une surveillance efficace des maladies liées au climat ; et à suivre, anticiper, gérer les risques sanitaires associés au changement climatique et à s’y adapter ;
inciter les responsables des établissements de santé à collaborer avec les secteurs déterminants pour la santé (notamment l’eau et l’assainissement, l’énergie, les transports, l’alimentation, l’urbanisme, l’environnement) afin de se préparer aux risques sanitaires supplémentaires posés par le changement climatique grâce à l’adoption d’une approche de résilience, et à promouvoir des pratiques écologiquement durables dans la prestation des services ;
fournir des outils pour aider les responsables des établissements de santé à évaluer leur résilience face aux menaces liées au changement climatique et leur durabilité environnementale, sur la base de l’utilisation appropriée des ressources (en particulier l’eau et l’énergie et les achats durables), et du rejet de matières dangereuses (biologiques, chimiques, radiologiques) dans leur environnement ;
promouvoir des mesures visant à garantir que les établissements de santé soient constamment et de plus en plus solides et continuent d’être efficaces et réactifs pour améliorer la santé et contribuer à réduire les inégalités et la vulnérabilité dans leur contexte local.
more
The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform.
Guidelines ...regarding the use of drugs to treat (rather than prevent) COVID-19 are included in a separate WHO document, Therapeutics and COVID-19: living guideline, that can via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform). Guidelines regarding the clinical management of COVID-19 patients are included in a further document, COVID-19 Clinical management: Living guideline, that can be accessed via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform).
more
A formulary of dermatological preparations and background information on therapeutic choices, production and dispensing. 2nd edition
Le Tchad reste confronté à un cycle récurrent de crises alimentaires et nutritionnelles ayant un impact négatif sur la santé et l’état nutritionnel des populations en général et celle des personnes les plus vulnérables que sont les enfants, les femmes enceintes et/ou allaitantes et les pe...rsonnes âgées en particulier.
more
These pocket guidelines provide evidence-based guidance on how to reduce the incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also i...nterweaves clinical, biochemical and epidemiological studies.
more
manuel de mise en oeuvre de l’OMS
Le Sénégal a réalisé des Enquêtes Démographiques et de Santé (EDS) en 1986, 1992, 1997, 2005, et 2010-2011. Au sortir de l’édition de 2010-2011, notre pays s’est engagé dans la mise en œuvre d’un programme d’enquêtes dont la périodicité de collecte de données est ramenée à un... an (EDScontinue). A la suite de la phase pilote du projet de l’enquête Continue (2012-2017) initiée par l’USAID, le Ministère de l’Economie, du Plan et de la Coopération à travers l’ANSD avec la collaboration du Ministère
de la Santé et de l’Action Sociale, s’est engagé pour pérenniser l’enquête Continue. Ce rapport présente les résultats de la deuxième année de pérennisation (2019).
more